Reuters logo
7 months ago
BRIEF-XTL Biopharmaceuticals says to pursue Sjögren's syndrome as 2nd indication for lead drug candidate
January 5, 2017 / 1:54 PM / 7 months ago

BRIEF-XTL Biopharmaceuticals says to pursue Sjögren's syndrome as 2nd indication for lead drug candidate

Jan 5 (Reuters) - X T L Biopharmaceuticals Ltd

* X T L Biopharmaceuticals - intends to pursue Sjögren's syndrome as second indication for its lead drug candidate HCDR1

* X T L Biopharmaceuticals - a patent application has been filed with U.S. Patent and trademark office for HCDR1 in treatment of Sjögren's syndrome Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below